SMART Health Cards: Vaccination & Testing Implementation Guide
1.0.0 - STU1

SMART Health Cards: Vaccination &amp; Testing Implementation Guide, published by HL7 International / Public Health. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-shc-vaccination-ig/ and changes regularly. See the Directory of published versions

## ValueSet: Immunization / All / CVX

Official URL: http://hl7.org/fhir/uv/shc-vaccination/ValueSet/immunization-all-cvx | Version: 1.0.0
Standards status: Trial-use | Maturity Level: 4 | Computable Name: ImmunizationAllCvxValueSet

Contains all CVX codes from https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx as of 2025-09-03. This list of codes will not update automatically, so please refer to this URL for the most up-to-date codes.the most up-to-date codes.

References

- Vaccination Profile - Allowable Data

### Logical Definition (CLD)

- Include these codes as defined in `http://hl7.org/fhir/sid/cvx`

  Code | Display
  54 | adenovirus, type 4
  55 | adenovirus, type 7
  82 | adenovirus, unspecified formulation
  24 | Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis
  19 | BCG
  27 | botulinum antitoxin
  26 | cholera, unspecified formulation
  29 | CMVIG
  56 | dengue fever tetravalent
  12 | diphtheria antitoxin
  28 | DT (pediatric)
  20 | DTaP
  106 | DTaP, 5 pertussis antigens
  107 | DTaP, unspecified formulation
  110 | DTaP-Hep B-IPV
  50 | DTaP-Hib
  120 | DTaP-Hib-IPV
  130 | DTaP-IPV
  22 | DTP-Hib
  102 | DTP-Hib-Hep B
  57 | hantavirus
  52 | Hep A, adult
  83 | Hep A, ped/adol, 2 dose
  84 | Hep A, ped/adol, 3 dose
  31 | Hep A, pediatric, unspecified formulation
  85 | Hep A, unspecified formulation
  104 | Hep A-Hep B
  30 | HBIG
  42 | Hep B, adolescent/high risk infant
  43 | Hep B, adult
  44 | Hep B, high-dosage, dialysis or IC
  45 | Hep B, unspecified formulation
  58 | Hep C
  59 | Hep E
  60 | herpes simplex 2
  46 | Hib (PRP-D)
  47 | Hib (HbOC)
  48 | Hib (PRP-T)
  49 | Hib (PRP-OMP)
  17 | Hib, unspecified formulation
  51 | Hib-Hep B
  61 | HIV
  118 | HPV, bivalent
  62 | HPV, quadrivalent
  86 | IG
  87 | IGIV
  14 | IG, unspecified formulation
  111 | Influenza, live, trivalent, intranasal, PF
  15 | influenza, split (incl. purified surface antigen)
  16 | influenza, whole
  88 | influenza, unspecified formulation
  123 | influenza, H5N1-1203
  10 | IPV
  89 | polio, unspecified formulation
  39 | Japanese encephalitis SC
  63 | Junin virus
  64 | leishmaniasis
  65 | leprosy
  66 | Lyme disease
  94 | MMRV
  67 | malaria
  68 | melanoma
  32 | meningococcal MPSV4
  103 | meningococcal C conjugate
  114 | meningococcal MCV4P
  108 | meningococcal ACWY, unspecified formulation
  69 | parainfluenza-3
  11 | pertussis
  23 | plague
  33 | pneumococcal polysaccharide PPV23
  100 | pneumococcal conjugate PCV 7
  109 | pneumococcal, unspecified formulation
  70 | Q fever
  18 | rabies, intramuscular injection
  40 | rabies, intradermal injection
  90 | rabies, unspecified formulation
  72 | rheumatic fever
  73 | Rift Valley fever
  34 | RIG
  119 | rotavirus, monovalent
  122 | rotavirus, unspecified formulation
  116 | rotavirus, pentavalent
  74 | rotavirus, tetravalent
  71 | RSV-IGIV
  93 | RSV-MAb
  38 | rubella/mumps
  76 | Staphylococcus bacterio lysate
  113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed
  115 | Tdap
  35 | tetanus toxoid, adsorbed
  112 | tetanus toxoid, unspecified formulation
  77 | Tick-borne encephalitis vaccine (non-US)
  13 | TIG
  95 | TST-OT tine test
  96 | TST-PPD intradermal
  97 | TST-PPD tine test
  98 | TST, unspecified formulation
  78 | tularemia vaccine
  91 | typhoid, unspecified formulation
  25 | typhoid, oral
  41 | typhoid, parenteral
  53 | typhoid, parenteral, AKD (U.S. military)
  101 | typhoid, ViCPs
  75 | Vaccinia (smallpox, mpox), live
  105 | vaccinia (smallpox) diluted
  79 | vaccinia immune globulin
  21 | varicella
  81 | VEE, inactivated
  80 | VEE, live
  92 | VEE, unspecified formulation
  36 | VZIG
  117 | VZIG (IND)
  37 | yellow fever live
  121 | zoster live
  998 | no vaccine administered
  999 | unknown
  99 | RESERVED - do not use
  133 | Pneumococcal conjugate PCV 13
  134 | Japanese Encephalitis IM
  137 | HPV, unspecified formulation
  136 | Meningococcal MCV4O
  135 | Influenza, high-dose, trivalent, PF
  131 | typhus, historical
  132 | DTaP-IPV-HIB-HEP B, historical
  128 | Novel Influenza-H1N1-09, all formulations
  125 | Novel Influenza-H1N1-09, nasal
  126 | Novel influenza-H1N1-09, preservative-free
  127 | Novel influenza-H1N1-09
  138 | Td (adult)
  139 | Td(adult) unspecified formulation
  140 | Influenza, split virus, trivalent, PF
  129 | Japanese Encephalitis, unspecified formulation
  141 | Influenza, split virus, trivalent, preservative
  142 | tetanus toxoid, not adsorbed
  143 | Adenovirus types 4 and 7
  144 | influenza, seasonal, intradermal, preservative free
  145 | RSV-MAb (new)
  146 | DTaP,IPV,Hib,HepB
  147 | meningococcal MCV4, unspecified formulation
  148 | Meningococcal C/Y-HIB PRP
  149 | Influenza, live, quadrivalent, intranasal
  150 | Influenza, split virus, quadrivalent, PF
  151 | influenza nasal, unspecified formulation
  152 | Pneumococcal Conjugate, unspecified formulation
  153 | Influenza, MDCK, trivalent, PF
  154 | Hep A, IG
  155 | Influenza, recombinant, trivalent, PF
  156 | Rho(D)-IG
  157 | Rho(D) -IG IM
  158 | Influenza, split virus, quadrivalent, preservative
  159 | Rho(D) - Unspecified formulation
  160 | Influenza A monovalent (H5N1), ADJUVANTED-2013
  801 | AS03 Adjuvant
  161 | Influenza, injectable,quadrivalent, preservative free, pediatric
  162 | meningococcal B, recombinant
  163 | meningococcal B, OMV
  164 | meningococcal B, unspecified
  165 | HPV9
  166 | influenza, intradermal, quadrivalent, preservative free
  167 | meningococcal, unknown serogroups
  168 | Influenza, adjuvanted, trivalent, PF
  169 | Hep A, live attenuated
  170 | DTAP/IPV/HIB - non-US
  171 | Influenza, MDCK, quadrivalent, PF
  172 | cholera, WC-rBS
  173 | cholera, BivWC
  174 | cholera, live attenuated
  175 | Rabies - IM Diploid cell culture
  176 | Rabies - IM fibroblast culture
  177 | PCV10
  178 | OPV bivalent
  179 | OPV ,monovalent, unspecified
  180 | tetanus immune globulin
  181 | anthrax immune globulin
  182 | OPV, Unspecified
  183 | Yellow fever vaccine live - alt
  184 | Yellow fever, unspecified
  185 | Influenza, recombinant, quadrivalent, PF
  186 | Influenza, MDCK, quadrivalent, preservative
  187 | zoster recombinant
  188 | zoster, unspecified formulation
  189 | HepB-CpG
  190 | Typhoid conjugate vaccine (TCV)
  191 | meningococcal A polysaccharide (non-US)
  192 | meningococcal AC polysaccharide (non-US)
  193 | Hep A-Hep B, pediatric/adolescent
  194 | Influenza, Southern Hemisphere
  195 | DT, IPV adsorbed
  196 | Td, adsorbed, preservative free, adult use, Lf unspecified
  197 | Influenza, high-dose, quadrivalent, PF
  200 | influenza, Southern Hemisphere, pediatric, preservative free
  201 | Influenza, Southern Hemisphere, quadrivalent, PF
  202 | influenza, Southern Hemisphere, quadrivalent, with preservative
  198 | DTP-hepB-Hib Pentavalent Non-US
  203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
  205 | Influenza, adjuvanted, quadrivalent, PF
  206 | Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection
  207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose
  208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose
  213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED
  210 | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL
  212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL
  204 | Ebola Zaire vaccine, live, recombinant, 1mL dose
  214 | Ebola, unspecified
  211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL
  500 | COVID-19 Non-US Vaccine, Product Unknown
  501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN)
  502 | COVID-19 IV Non-US Vaccine (COVAXIN)
  503 | COVID-19 LAV Non-US Vaccine (COVIVAC)
  504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light)
  505 | COVID-19 VVnr Non-US Vaccine (Sputnik V)
  506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology
  507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)
  508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)
  509 | COVID-19 PS Non-US Vaccine (EpiVacCorona)
  510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)
  511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
  215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF
  216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF
  219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose
  217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose
  218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose
  220 | HepB recombinant, 3-antigen, Al(OH)3
  221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose
  222 | Tick-borne encephalitis, unspecified
  223 | Tick-borne encephalitis, inactivated, PF, 0.25mL
  224 | Tick-borne encephalitis, inactivated, PF, 0.5mL
  225 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL
  226 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL
  512 | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz)
  513 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax)
  514 | SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D)
  515 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901)
  516 | COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
  517 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)
  227 | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose
  228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose
  229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose
  301 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose
  300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose
  230 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL
  518 | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)
  519 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna
  520 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech
  521 | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK
  231 | influenza, Southern Hemisphere, high-dose, quadrivalent
  303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
  304 | Respiratory syncytial virus (RSV), unspecified
  305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF
  306 | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months
  307 | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months
  313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL
  308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL
  309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL
  310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL
  312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL
  311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL
  315 | Respiratory syncytial virus (RSV) MAB, unspecified
  314 | Respiratory syncytial virus (RSV) vaccine, unspecified
  316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF
  317 | Chikungunya live attenuated vaccine, 0.5 mL, PF
  318 | Anthrax, post-exposure prophylaxis
  319 | Anthrax vaccine, unspecified
  320 | Influenza, MDCK, trivalent, preservative
  321 | Influenza-avian, H5N8, monovalent, PF
  322 | Influenza-avian, H5N8, monovalent, preservative
  324 | Poliovirus, inactivated, fractional-dose (fIPV)
  323 | Influenza-avian, H5, unspecified formulation
  326 | RSV, mRNA, injectable, PF
  327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF
  328 | Meningococcal oligosaccharide (MenACWY), (MenB), PF
  329 | Chikungunya, VLP, recombinant, 0.8 mL, PF
  330 | Dengue fever, unspecified
  331 | Influenza, Southern Hemisphere, trivalent, PF
  325 | Vaccinia (smallpox, mpox), unspecified
  332 | RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF
  333 | Influenza, live, trivalent, intranasal, self/caregiver admin, PF
  302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose

### Expansion

Expansion from tx.fhir.org based on codesystem Vaccine Administered Code Set (CVX) version20250715

This value set contains 278 concepts

Code | System | Display
54 | http://hl7.org/fhir/sid/cvx | adenovirus, type 4
55 | http://hl7.org/fhir/sid/cvx | adenovirus, type 7
82 | http://hl7.org/fhir/sid/cvx | adenovirus, unspecified formulation
24 | http://hl7.org/fhir/sid/cvx | Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis
19 | http://hl7.org/fhir/sid/cvx | BCG
27 | http://hl7.org/fhir/sid/cvx | botulinum antitoxin
26 | http://hl7.org/fhir/sid/cvx | cholera, unspecified formulation
29 | http://hl7.org/fhir/sid/cvx | CMVIG
56 | http://hl7.org/fhir/sid/cvx | dengue fever tetravalent
12 | http://hl7.org/fhir/sid/cvx | diphtheria antitoxin
28 | http://hl7.org/fhir/sid/cvx | DT (pediatric)
20 | http://hl7.org/fhir/sid/cvx | DTaP
106 | http://hl7.org/fhir/sid/cvx | DTaP, 5 pertussis antigens
107 | http://hl7.org/fhir/sid/cvx | DTaP, unspecified formulation
110 | http://hl7.org/fhir/sid/cvx | DTaP-Hep B-IPV
50 | http://hl7.org/fhir/sid/cvx | DTaP-Hib
120 | http://hl7.org/fhir/sid/cvx | DTaP-Hib-IPV
130 | http://hl7.org/fhir/sid/cvx | DTaP-IPV
22 | http://hl7.org/fhir/sid/cvx | DTP-Hib
102 | http://hl7.org/fhir/sid/cvx | DTP-Hib-Hep B
57 | http://hl7.org/fhir/sid/cvx | hantavirus
52 | http://hl7.org/fhir/sid/cvx | Hep A, adult
83 | http://hl7.org/fhir/sid/cvx | Hep A, ped/adol, 2 dose
84 | http://hl7.org/fhir/sid/cvx | Hep A, ped/adol, 3 dose
31 | http://hl7.org/fhir/sid/cvx | Hep A, pediatric, unspecified formulation
85 | http://hl7.org/fhir/sid/cvx | Hep A, unspecified formulation
104 | http://hl7.org/fhir/sid/cvx | Hep A-Hep B
30 | http://hl7.org/fhir/sid/cvx | HBIG
42 | http://hl7.org/fhir/sid/cvx | Hep B, adolescent/high risk infant
43 | http://hl7.org/fhir/sid/cvx | Hep B, adult
44 | http://hl7.org/fhir/sid/cvx | Hep B, high-dosage, dialysis or IC
45 | http://hl7.org/fhir/sid/cvx | Hep B, unspecified formulation
58 | http://hl7.org/fhir/sid/cvx | Hep C
59 | http://hl7.org/fhir/sid/cvx | Hep E
60 | http://hl7.org/fhir/sid/cvx | herpes simplex 2
46 | http://hl7.org/fhir/sid/cvx | Hib (PRP-D)
47 | http://hl7.org/fhir/sid/cvx | Hib (HbOC)
48 | http://hl7.org/fhir/sid/cvx | Hib (PRP-T)
49 | http://hl7.org/fhir/sid/cvx | Hib (PRP-OMP)
17 | http://hl7.org/fhir/sid/cvx | Hib, unspecified formulation
51 | http://hl7.org/fhir/sid/cvx | Hib-Hep B
61 | http://hl7.org/fhir/sid/cvx | HIV
118 | http://hl7.org/fhir/sid/cvx | HPV, bivalent
62 | http://hl7.org/fhir/sid/cvx | HPV, quadrivalent
86 | http://hl7.org/fhir/sid/cvx | IG
87 | http://hl7.org/fhir/sid/cvx | IGIV
14 | http://hl7.org/fhir/sid/cvx | IG, unspecified formulation
111 | http://hl7.org/fhir/sid/cvx | Influenza, live, trivalent, intranasal, PF
15 | http://hl7.org/fhir/sid/cvx | influenza, split (incl. purified surface antigen)
16 | http://hl7.org/fhir/sid/cvx | influenza, whole
88 | http://hl7.org/fhir/sid/cvx | influenza, unspecified formulation
123 | http://hl7.org/fhir/sid/cvx | influenza, H5N1-1203
10 | http://hl7.org/fhir/sid/cvx | IPV
89 | http://hl7.org/fhir/sid/cvx | polio, unspecified formulation
39 | http://hl7.org/fhir/sid/cvx | Japanese encephalitis SC
63 | http://hl7.org/fhir/sid/cvx | Junin virus
64 | http://hl7.org/fhir/sid/cvx | leishmaniasis
65 | http://hl7.org/fhir/sid/cvx | leprosy
66 | http://hl7.org/fhir/sid/cvx | Lyme disease
94 | http://hl7.org/fhir/sid/cvx | MMRV
67 | http://hl7.org/fhir/sid/cvx | malaria
68 | http://hl7.org/fhir/sid/cvx | melanoma
32 | http://hl7.org/fhir/sid/cvx | meningococcal MPSV4
103 | http://hl7.org/fhir/sid/cvx | meningococcal C conjugate
114 | http://hl7.org/fhir/sid/cvx | meningococcal MCV4P
108 | http://hl7.org/fhir/sid/cvx | meningococcal ACWY, unspecified formulation
69 | http://hl7.org/fhir/sid/cvx | parainfluenza-3
11 | http://hl7.org/fhir/sid/cvx | pertussis
23 | http://hl7.org/fhir/sid/cvx | plague
33 | http://hl7.org/fhir/sid/cvx | pneumococcal polysaccharide PPV23
100 | http://hl7.org/fhir/sid/cvx | pneumococcal conjugate PCV 7
109 | http://hl7.org/fhir/sid/cvx | pneumococcal, unspecified formulation
70 | http://hl7.org/fhir/sid/cvx | Q fever
18 | http://hl7.org/fhir/sid/cvx | rabies, intramuscular injection
40 | http://hl7.org/fhir/sid/cvx | rabies, intradermal injection
90 | http://hl7.org/fhir/sid/cvx | rabies, unspecified formulation
72 | http://hl7.org/fhir/sid/cvx | rheumatic fever
73 | http://hl7.org/fhir/sid/cvx | Rift Valley fever
34 | http://hl7.org/fhir/sid/cvx | RIG
119 | http://hl7.org/fhir/sid/cvx | rotavirus, monovalent
122 | http://hl7.org/fhir/sid/cvx | rotavirus, unspecified formulation
116 | http://hl7.org/fhir/sid/cvx | rotavirus, pentavalent
74 | http://hl7.org/fhir/sid/cvx | rotavirus, tetravalent
71 | http://hl7.org/fhir/sid/cvx | RSV-IGIV
93 | http://hl7.org/fhir/sid/cvx | RSV-MAb
38 | http://hl7.org/fhir/sid/cvx | rubella/mumps
76 | http://hl7.org/fhir/sid/cvx | Staphylococcus bacterio lysate
113 | http://hl7.org/fhir/sid/cvx | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed
115 | http://hl7.org/fhir/sid/cvx | Tdap
35 | http://hl7.org/fhir/sid/cvx | tetanus toxoid, adsorbed
112 | http://hl7.org/fhir/sid/cvx | tetanus toxoid, unspecified formulation
77 | http://hl7.org/fhir/sid/cvx | Tick-borne encephalitis vaccine (non-US)
13 | http://hl7.org/fhir/sid/cvx | TIG
95 | http://hl7.org/fhir/sid/cvx | TST-OT tine test
96 | http://hl7.org/fhir/sid/cvx | TST-PPD intradermal
97 | http://hl7.org/fhir/sid/cvx | TST-PPD tine test
98 | http://hl7.org/fhir/sid/cvx | TST, unspecified formulation
78 | http://hl7.org/fhir/sid/cvx | tularemia vaccine
91 | http://hl7.org/fhir/sid/cvx | typhoid, unspecified formulation
25 | http://hl7.org/fhir/sid/cvx | typhoid, oral
41 | http://hl7.org/fhir/sid/cvx | typhoid, parenteral
53 | http://hl7.org/fhir/sid/cvx | typhoid, parenteral, AKD (U.S. military)
101 | http://hl7.org/fhir/sid/cvx | typhoid, ViCPs
75 | http://hl7.org/fhir/sid/cvx | Vaccinia (smallpox, mpox), live
105 | http://hl7.org/fhir/sid/cvx | vaccinia (smallpox) diluted
79 | http://hl7.org/fhir/sid/cvx | vaccinia immune globulin
21 | http://hl7.org/fhir/sid/cvx | varicella
81 | http://hl7.org/fhir/sid/cvx | VEE, inactivated
80 | http://hl7.org/fhir/sid/cvx | VEE, live
92 | http://hl7.org/fhir/sid/cvx | VEE, unspecified formulation
36 | http://hl7.org/fhir/sid/cvx | VZIG
117 | http://hl7.org/fhir/sid/cvx | VZIG (IND)
37 | http://hl7.org/fhir/sid/cvx | yellow fever live
121 | http://hl7.org/fhir/sid/cvx | zoster live
998 | http://hl7.org/fhir/sid/cvx | no vaccine administered
999 | http://hl7.org/fhir/sid/cvx | unknown
99 | http://hl7.org/fhir/sid/cvx | RESERVED - do not use
133 | http://hl7.org/fhir/sid/cvx | Pneumococcal conjugate PCV 13
134 | http://hl7.org/fhir/sid/cvx | Japanese Encephalitis IM
137 | http://hl7.org/fhir/sid/cvx | HPV, unspecified formulation
136 | http://hl7.org/fhir/sid/cvx | Meningococcal MCV4O
135 | http://hl7.org/fhir/sid/cvx | Influenza, high-dose, trivalent, PF
131 | http://hl7.org/fhir/sid/cvx | typhus, historical
132 | http://hl7.org/fhir/sid/cvx | DTaP-IPV-HIB-HEP B, historical
128 | http://hl7.org/fhir/sid/cvx | Novel Influenza-H1N1-09, all formulations
125 | http://hl7.org/fhir/sid/cvx | Novel Influenza-H1N1-09, nasal
126 | http://hl7.org/fhir/sid/cvx | Novel influenza-H1N1-09, preservative-free
127 | http://hl7.org/fhir/sid/cvx | Novel influenza-H1N1-09
138 | http://hl7.org/fhir/sid/cvx | Td (adult)
139 | http://hl7.org/fhir/sid/cvx | Td(adult) unspecified formulation
140 | http://hl7.org/fhir/sid/cvx | Influenza, split virus, trivalent, PF
129 | http://hl7.org/fhir/sid/cvx | Japanese Encephalitis, unspecified formulation
141 | http://hl7.org/fhir/sid/cvx | Influenza, split virus, trivalent, preservative
142 | http://hl7.org/fhir/sid/cvx | tetanus toxoid, not adsorbed
143 | http://hl7.org/fhir/sid/cvx | Adenovirus types 4 and 7
144 | http://hl7.org/fhir/sid/cvx | influenza, seasonal, intradermal, preservative free
145 | http://hl7.org/fhir/sid/cvx | RSV-MAb (new)
146 | http://hl7.org/fhir/sid/cvx | DTaP,IPV,Hib,HepB
147 | http://hl7.org/fhir/sid/cvx | meningococcal MCV4, unspecified formulation
148 | http://hl7.org/fhir/sid/cvx | Meningococcal C/Y-HIB PRP
149 | http://hl7.org/fhir/sid/cvx | Influenza, live, quadrivalent, intranasal
150 | http://hl7.org/fhir/sid/cvx | Influenza, split virus, quadrivalent, PF
151 | http://hl7.org/fhir/sid/cvx | influenza nasal, unspecified formulation
152 | http://hl7.org/fhir/sid/cvx | Pneumococcal Conjugate, unspecified formulation
153 | http://hl7.org/fhir/sid/cvx | Influenza, MDCK, trivalent, PF
154 | http://hl7.org/fhir/sid/cvx | Hep A, IG
155 | http://hl7.org/fhir/sid/cvx | Influenza, recombinant, trivalent, PF
156 | http://hl7.org/fhir/sid/cvx | Rho(D)-IG
157 | http://hl7.org/fhir/sid/cvx | Rho(D) -IG IM
158 | http://hl7.org/fhir/sid/cvx | Influenza, split virus, quadrivalent, preservative
159 | http://hl7.org/fhir/sid/cvx | Rho(D) - Unspecified formulation
160 | http://hl7.org/fhir/sid/cvx | Influenza A monovalent (H5N1), ADJUVANTED-2013
801 | http://hl7.org/fhir/sid/cvx | AS03 Adjuvant
161 | http://hl7.org/fhir/sid/cvx | Influenza, injectable,quadrivalent, preservative free, pediatric
162 | http://hl7.org/fhir/sid/cvx | meningococcal B, recombinant
163 | http://hl7.org/fhir/sid/cvx | meningococcal B, OMV
164 | http://hl7.org/fhir/sid/cvx | meningococcal B, unspecified
165 | http://hl7.org/fhir/sid/cvx | HPV9
166 | http://hl7.org/fhir/sid/cvx | influenza, intradermal, quadrivalent, preservative free
167 | http://hl7.org/fhir/sid/cvx | meningococcal, unknown serogroups
168 | http://hl7.org/fhir/sid/cvx | Influenza, adjuvanted, trivalent, PF
169 | http://hl7.org/fhir/sid/cvx | Hep A, live attenuated
170 | http://hl7.org/fhir/sid/cvx | DTAP/IPV/HIB - non-US
171 | http://hl7.org/fhir/sid/cvx | Influenza, MDCK, quadrivalent, PF
172 | http://hl7.org/fhir/sid/cvx | cholera, WC-rBS
173 | http://hl7.org/fhir/sid/cvx | cholera, BivWC
174 | http://hl7.org/fhir/sid/cvx | cholera, live attenuated
175 | http://hl7.org/fhir/sid/cvx | Rabies - IM Diploid cell culture
176 | http://hl7.org/fhir/sid/cvx | Rabies - IM fibroblast culture
177 | http://hl7.org/fhir/sid/cvx | PCV10
178 | http://hl7.org/fhir/sid/cvx | OPV bivalent
179 | http://hl7.org/fhir/sid/cvx | OPV ,monovalent, unspecified
180 | http://hl7.org/fhir/sid/cvx | tetanus immune globulin
181 | http://hl7.org/fhir/sid/cvx | anthrax immune globulin
182 | http://hl7.org/fhir/sid/cvx | OPV, Unspecified
183 | http://hl7.org/fhir/sid/cvx | Yellow fever vaccine live - alt
184 | http://hl7.org/fhir/sid/cvx | Yellow fever, unspecified
185 | http://hl7.org/fhir/sid/cvx | Influenza, recombinant, quadrivalent, PF
186 | http://hl7.org/fhir/sid/cvx | Influenza, MDCK, quadrivalent, preservative
187 | http://hl7.org/fhir/sid/cvx | zoster recombinant
188 | http://hl7.org/fhir/sid/cvx | zoster, unspecified formulation
189 | http://hl7.org/fhir/sid/cvx | HepB-CpG
190 | http://hl7.org/fhir/sid/cvx | Typhoid conjugate vaccine (TCV)
191 | http://hl7.org/fhir/sid/cvx | meningococcal A polysaccharide (non-US)
192 | http://hl7.org/fhir/sid/cvx | meningococcal AC polysaccharide (non-US)
193 | http://hl7.org/fhir/sid/cvx | Hep A-Hep B, pediatric/adolescent
194 | http://hl7.org/fhir/sid/cvx | Influenza, Southern Hemisphere
195 | http://hl7.org/fhir/sid/cvx | DT, IPV adsorbed
196 | http://hl7.org/fhir/sid/cvx | Td, adsorbed, preservative free, adult use, Lf unspecified
197 | http://hl7.org/fhir/sid/cvx | Influenza, high-dose, quadrivalent, PF
200 | http://hl7.org/fhir/sid/cvx | influenza, Southern Hemisphere, pediatric, preservative free
201 | http://hl7.org/fhir/sid/cvx | Influenza, Southern Hemisphere, quadrivalent, PF
202 | http://hl7.org/fhir/sid/cvx | influenza, Southern Hemisphere, quadrivalent, with preservative
198 | http://hl7.org/fhir/sid/cvx | DTP-hepB-Hib Pentavalent Non-US
203 | http://hl7.org/fhir/sid/cvx | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
205 | http://hl7.org/fhir/sid/cvx | Influenza, adjuvanted, quadrivalent, PF
206 | http://hl7.org/fhir/sid/cvx | Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection
207 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose
208 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose
213 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED
210 | http://hl7.org/fhir/sid/cvx | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL
212 | http://hl7.org/fhir/sid/cvx | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL
204 | http://hl7.org/fhir/sid/cvx | Ebola Zaire vaccine, live, recombinant, 1mL dose
214 | http://hl7.org/fhir/sid/cvx | Ebola, unspecified
211 | http://hl7.org/fhir/sid/cvx | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL
500 | http://hl7.org/fhir/sid/cvx | COVID-19 Non-US Vaccine, Product Unknown
501 | http://hl7.org/fhir/sid/cvx | COVID-19 IV Non-US Vaccine (QAZCOVID-IN)
502 | http://hl7.org/fhir/sid/cvx | COVID-19 IV Non-US Vaccine (COVAXIN)
503 | http://hl7.org/fhir/sid/cvx | COVID-19 LAV Non-US Vaccine (COVIVAC)
504 | http://hl7.org/fhir/sid/cvx | COVID-19 VVnr Non-US Vaccine (Sputnik Light)
505 | http://hl7.org/fhir/sid/cvx | COVID-19 VVnr Non-US Vaccine (Sputnik V)
506 | http://hl7.org/fhir/sid/cvx | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology
507 | http://hl7.org/fhir/sid/cvx | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)
508 | http://hl7.org/fhir/sid/cvx | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)
509 | http://hl7.org/fhir/sid/cvx | COVID-19 PS Non-US Vaccine (EpiVacCorona)
510 | http://hl7.org/fhir/sid/cvx | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)
511 | http://hl7.org/fhir/sid/cvx | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
215 | http://hl7.org/fhir/sid/cvx | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF
216 | http://hl7.org/fhir/sid/cvx | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF
219 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose
217 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose
218 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose
220 | http://hl7.org/fhir/sid/cvx | HepB recombinant, 3-antigen, Al(OH)3
221 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose
222 | http://hl7.org/fhir/sid/cvx | Tick-borne encephalitis, unspecified
223 | http://hl7.org/fhir/sid/cvx | Tick-borne encephalitis, inactivated, PF, 0.25mL
224 | http://hl7.org/fhir/sid/cvx | Tick-borne encephalitis, inactivated, PF, 0.5mL
225 | http://hl7.org/fhir/sid/cvx | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL
226 | http://hl7.org/fhir/sid/cvx | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL
512 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz)
513 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax)
514 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D)
515 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901)
516 | http://hl7.org/fhir/sid/cvx | COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
517 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)
227 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose
228 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose
229 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose
301 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose
300 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose
230 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL
518 | http://hl7.org/fhir/sid/cvx | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)
519 | http://hl7.org/fhir/sid/cvx | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna
520 | http://hl7.org/fhir/sid/cvx | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech
521 | http://hl7.org/fhir/sid/cvx | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK
231 | http://hl7.org/fhir/sid/cvx | influenza, Southern Hemisphere, high-dose, quadrivalent
303 | http://hl7.org/fhir/sid/cvx | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
304 | http://hl7.org/fhir/sid/cvx | Respiratory syncytial virus (RSV), unspecified
305 | http://hl7.org/fhir/sid/cvx | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF
306 | http://hl7.org/fhir/sid/cvx | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months
307 | http://hl7.org/fhir/sid/cvx | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months
313 | http://hl7.org/fhir/sid/cvx | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL
308 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL
309 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL
310 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL
312 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL
311 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL
315 | http://hl7.org/fhir/sid/cvx | Respiratory syncytial virus (RSV) MAB, unspecified
314 | http://hl7.org/fhir/sid/cvx | Respiratory syncytial virus (RSV) vaccine, unspecified
316 | http://hl7.org/fhir/sid/cvx | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF
317 | http://hl7.org/fhir/sid/cvx | Chikungunya live attenuated vaccine, 0.5 mL, PF
318 | http://hl7.org/fhir/sid/cvx | Anthrax, post-exposure prophylaxis
319 | http://hl7.org/fhir/sid/cvx | Anthrax vaccine, unspecified
320 | http://hl7.org/fhir/sid/cvx | Influenza, MDCK, trivalent, preservative
321 | http://hl7.org/fhir/sid/cvx | Influenza-avian, H5N8, monovalent, PF
322 | http://hl7.org/fhir/sid/cvx | Influenza-avian, H5N8, monovalent, preservative
324 | http://hl7.org/fhir/sid/cvx | Poliovirus, inactivated, fractional-dose (fIPV)
323 | http://hl7.org/fhir/sid/cvx | Influenza-avian, H5, unspecified formulation
326 | http://hl7.org/fhir/sid/cvx | RSV, mRNA, injectable, PF
327 | http://hl7.org/fhir/sid/cvx | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF
328 | http://hl7.org/fhir/sid/cvx | Meningococcal oligosaccharide (MenACWY), (MenB), PF
329 | http://hl7.org/fhir/sid/cvx | Chikungunya, VLP, recombinant, 0.8 mL, PF
330 | http://hl7.org/fhir/sid/cvx | Dengue fever, unspecified
331 | http://hl7.org/fhir/sid/cvx | Influenza, Southern Hemisphere, trivalent, PF
325 | http://hl7.org/fhir/sid/cvx | Vaccinia (smallpox, mpox), unspecified
332 | http://hl7.org/fhir/sid/cvx | RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF
333 | http://hl7.org/fhir/sid/cvx | Influenza, live, trivalent, intranasal, self/caregiver admin, PF
302 | http://hl7.org/fhir/sid/cvx | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose

Explanation of the columns that may appear on this page:

Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System | The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code | The code (used as the code in the resource instance)
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition | An explanation of the meaning of the concept
Comments | Additional notes about how to use the code